Date: 2012-01-27
Type of information:
phase:
Announcement: initiation
Company: Cancer Research UK (UK)
Product: AT9283
Action mechanism: AT9283 belongs to a new class of drugs called aurora kinase inhibitors. Aurora kinases are essential in cell division. AT9238 prevents growth and survival of cancer cells by blocking the action of two key aurora kinase proteins.
Disease: acute lymphoblastic leukaemia
acute myeloid leukaemia
Therapeutic area: Cancer Oncology
Country: UK
Trial
details: In this first-in-child study, 15 children with acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML) will receive a treatment called AT9283. They will receive the drug intravenously in three separate, consecutive 24-hour infusions over 72 hours, in 21-day cycles.
The trial is led by Great North Children’s Hospital, Newcastle upon Tyne and is also running at four other clinical centres. The trial will also run at four other centres across the UK: Leeds General Infirmary; Royal Manchester Children’s Hospital, Birmingham Children\'s Hospital and Royal Marsden Hospital, Sutton.
Latest
news: Cancer Research UK’s Drug Development Office has opened the first trial of a new type of drug to treat children aged from six months to 18 years with acute leukaemia, who are no longer responding to treatment. The trial is led by Great North Children’s Hospital, Newcastle upon Tyne and is also running at four other clinical centres. The trial is funded, managed and sponsored by the charity’s Drug Development Office (DDO) and the drug is provided by Astex Pharmaceuticals.
